Document Detail

Integrated network analysis of transcriptomic and proteomic data in psoriasis.
Jump to Full Text
MedLine Citation:
PMID:  20377895     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Psoriasis is complex inflammatory skin pathology of autoimmune origin. Several cell types are perturbed in this pathology, and underlying signaling events are complex and still poorly understood.
RESULTS: In order to gain insight into molecular machinery underlying the disease, we conducted a comprehensive meta-analysis of proteomics and transcriptomics of psoriatic lesions from independent studies. Network-based analysis revealed similarities in regulation at both proteomics and transcriptomics level. We identified a group of transcription factors responsible for overexpression of psoriasis genes and a number of previously unknown signaling pathways that may play a role in this process. We also evaluated functional synergy between transcriptomics and proteomics results.
CONCLUSIONS: We developed network-based methodology for integrative analysis of high throughput data sets of different types. Investigation of proteomics and transcriptomics data sets on psoriasis revealed versatility in regulatory machinery underlying pathology and showed complementarities between two levels of cellular organization.
Authors:
Eleonora Piruzian; Sergey Bruskin; Alex Ishkin; Rustam Abdeev; Sergey Moshkovskii; Stanislav Melnik; Yuri Nikolsky; Tatiana Nikolskaya
Related Documents :
15144185 - Use of statistical methods for estimation of total number of charges in a mass spectrom...
11542215 - The dust distribution within the inner coma of comet p/halley 1982i: encounter by giott...
19233895 - Supervised feature selection in mass spectrometry-based proteomic profiling by blockwis...
19596695 - Development and evaluation of normalization methods for label-free relative quantificat...
20483415 - Evaluation of a mixed approach combining stationary and wearable systems to monitor gai...
21558055 - Combination of canonical correlation analysis and empirical mode decomposition applied ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-04-08
Journal Detail:
Title:  BMC systems biology     Volume:  4     ISSN:  1752-0509     ISO Abbreviation:  BMC Syst Biol     Publication Date:  2010  
Date Detail:
Created Date:  2010-05-17     Completed Date:  2010-07-28     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101301827     Medline TA:  BMC Syst Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  41     Citation Subset:  IM    
Affiliation:
Vavilov Institute of General Genetics, Russian Academy of Sciences, Gubkina St, 3 GSP-1, 119991 Moscow, Russia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biopsy
Female
Gene Expression Profiling*
Humans
Inflammation
Male
Models, Genetic
Models, Statistical
Oligonucleotide Array Sequence Analysis
Proteomics / methods*
Psoriasis / metabolism*
Skin / pathology
Systems Biology
Transcription, Genetic*
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Syst Biol
ISSN: 1752-0509
Publisher: BioMed Central
Article Information
Download PDF
Copyright ?2010 Piruzian et al; licensee BioMed Central Ltd.
open-access:
Received Day: 30 Month: 11 Year: 2009
Accepted Day: 8 Month: 4 Year: 2010
collection publication date: Year: 2010
Electronic publication date: Day: 8 Month: 4 Year: 2010
Volume: 4First Page: 41 Last Page: 41
Publisher Id: 1752-0509-4-41
PubMed Id: 20377895
DOI: 10.1186/1752-0509-4-41

Integrated network analysis of transcriptomic and proteomic data in psoriasis
Eleonora Piruzian1 Email: eleopiru@vigg.ru
Sergey Bruskin1 Email: sergey.bruskin@gmail.com
Alex Ishkin12 Email: ishkin@genego.com
Rustam Abdeev3 Email: art-arm@mail.ru
Sergey Moshkovskii4 Email: smosh@mail.ru
Stanislav Melnik4 Email: g_rat@rambler.ru
Yuri Nikolsky2 Email: yuri@genego.com
Tatiana Nikolskaya12 Email: tatiana@genego.com
1Vavilov Institute of General Genetics, Russian Academy of Sciences, Gubkina St, 3 GSP-1, 119991 Moscow, Russia
2GeneGo, Inc, Saint Joseph, MI, USA
3Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Kosigina str, 4, 119991 Moscow, Russia
4Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, 10 Pogodinskaya st, 119121 Moscow, Russia

Background

Psoriasis vulgaris is one of the most prevalent chronic inflammatory skin diseases affecting approximately 2% of individuals in Western societies, and found worldwide in all populations. Psoriasis is a complex disease affecting cellular, gene and protein levels and presented as skin lesions. The skin lesions are characterized by abnormal keratinocyte differentiation, hyperproliferation of keratinocytes, and infiltration of inflammatory cells [1,2]. The mechanisms of psoriasis pathology are complex and involve genetic and environmental factors. As we gain more knowledge about molecular pathways implicated in the disease, novel therapies emerge (such as etanercept and infliximab that target TNF-? or CD11a- mediated pathways [3,4]). In recent years, microarray mRNA expression profiling [5-8] of lesional psoriatic skin revealed over 1,300 differentially expressed genes. Enrichment analysis (EA) showed that these genes encode proteins involved in regeneration, hyperkeratosis, metabolic function, immune response, and inflammation and revealed a number of modulating signaling pathways. These efforts may help to develop new-generation drugs.

However, enrichment analysis limits our understanding of altered molecular interactions in psoriasis as it provides a relative ranking based on ontology terms resulting in the representation of fragmented and disconnected perturbed pathways. Furthermore, analysis of gene expression alone is not sufficient for understanding the whole variety of pathological changes at different levels of cellular organization. Indeed, new methodologies have been applied to the analysis of OMICs data in complex diseases that include algorithm-based biological network analysis [9-13] and meta-analysis of multiple datasets of different types [14-19]. Here, we applied several techniques of network and meta-analysis to reveal the similarities and differences between transcriptomics- and proteomics-level perturbations in psoriasis lesions. We particularly focused on revealing novel regulatory pathways playing a role in psoriasis development and progression.


Methods
Skin biopsies

Acquisition of the human tissue was approved by the Vavilov Institute of General Genetics of Russian Academy of Sciences review board and the study was conducted after patient's consent and according to the Declaration of Helsinki Principles.

A total of 6 paired nonlesional and lesional (all were plaque-type) skin biopsies from 3 psoriatic patients were profiled using 2D electrophoresis. All the donors who gave biopsy tissue (both healthy controls and individuals with psoriasis) provided a written informed consent for the tissue to be taken and used in this study. Clinical data for all patients are listed in Additional file 1.

Full-thickness punch biopsies were taken from uninvolved skin (at least 2 cm distant from any psoriatic lesion; 6 mm diameter) and from the involved margin of a psoriatic plaque (6 mm diameter) from every patient.

Sample preparation

Skin biopsies from lesional (n = 3) and non-lesional (n = 3) skin (~50 mg each) were mechanically homogenized on ice with mortar and pestle in solubilization buffer comprised of 7 M urea (Fisher Scientific), 2 M thiourea (MERK), 4% (w/v) CHAPS (Fluka), 0.5% (w/v) Triton X-100 (ICN), 0.5%(w/v) ampholines 3/10 (Bio-Rad), 20 mM Tris base (Fisher Scientific), 1 mM MgCl2 (Fluka), and 0.2 mM PMSF (Acros). The amount of solubilization buffer taken per sample was seven times tissue wet weight. Samples were then carefully sonicated at 4?C for 15 sec (3 bursts for 5 sec) with Bandelin sonicator at 50% power output. Following homogenization and sonication DTT (Acros) was added to reach the final concentration of 65 mM, and samples left at 4?C for 30 min. Then Na2EDTA was added (2 mM final) and mixture was incubated for additional 2 h and then centrifuged at 12,000 ? g for 10 min to remove insoluble debris. Relative protein concentration was determined with GS-800 Calibrated Densitometer (Bio-Rad) after 1D-SDS-PAGE of 3 ?l sample solution loaded on 8 ? 9 cm mini-gel stained with Coomassie R-250 after electrophoresis.

Two-dimensional electrophoresis

For the first dimension CA-IEF method was used [20]. Glass tubes 20 ? 1.5 mm (Bio-Rad) was filled with gel mixture containing 8.3 M urea (Fisher Scientific), 4% (w/v) acrylamide monomers (Acros), 2% CHAPS (Fluka), 1.6% (w/v) 5/8 and 0.4% (w/v) 3/10 ampholines (Bio-Rad), loaded with 120 ?g protein and run 15 min at 200 V, 30 min at 300 V, 16 hrs at 400 V, and 1 h at 800 V. Isoelectrofocusing was performed in Protean II xi cell (Bio-Rad). Before second dimension gels were extruded from tubes and equilibrated in 60 mM Tris-buffer pH 6.8, containing 2% (w/v) SDS, 10% (w/v) glycerol, and 1% (w/v) DTT for 30 min. For protein separation in the second dimension, 9-16% linear gradient slab gels prepared according to the standard protocol [20] were used.

Gel image analysis

Protein spots on 2-DE gels were visualized by silver staining [21] and scanned with resolution 300 dpi. Images were analyzed using Melanie III software (GeneBio, Switzerland). The conventional analysis involved (i) protein spot relative volume (%Vol) determination, which was expressed as the sum of pixel intensities in the certain spot divided to the sum of pixel intensities in all spots on the gel; (ii) gel alignment; and (iii) spot matching. Further, sets of %Vol values for every spot were processed by Student test, thereby testing whether there was a significant variation of the certain protein level between two specified groups.

Protein identification by MALDI-TOF mass-spectrometry

Protein spots were cut out (~3 mm3) from 2-DE gels, destained, and in-gel digested with trypsin. Mass-spectrometry of trypsin digested proteins (spots No. 1,2,3,4) was performed using a Microflex MALDI-TOF mass-spectrometer (Bruker, Germany). Peptide samples (0.2-1 ?l) were mixed with an equal volume of 2,5-dihydroxybenzoic acid solution (20 mg/ml; Sigma, USA) in 20% acetonitrile and 0.1% trifluoroacetic acid, and the resulting droplets were dried in air. Mass-spectra were obtained for mass range from 800 to 4000 daltons in reflection mode and calibrated using internal standards (trypsin autolysis peaks, MH+ 1046.54, 2212.10 daltons). Peptide peak lists were formed by the SNAP algorithm (XMass software, Bruker). Proteins were identified using the Mascot database search engine. The search parameters were as follows: mass tolerance 100 ppm, NCBI protein sequence database, Homo sapiens taxon, one missed cleavage, variable modifications by propionamide for cysteines and oxidation for methionines.

Low molecular weight proteins (9-20 kDa, spots No. 5,6,7,8,9,10) were identified using nanoLC-MS/MS mass-spectrometry for higher convenience, regarding lack of cleavage sites in such proteins. Analysis of trypsin digest was performed on electrospray ion trap (XCT Ultra Ion Trap Chip Cube 6330 series, Agilent) equipped with chip-cube head. One ?l of each sample was subjected (flow rate 3 ?l/min) onto reverse-phase in-chip column (40 nl capacity) for 10 minutes under isocratic buffer (5% acetonitrile in 0.1% TFA). Following sample application peptides were separated by linear gradient (0.3 ?l/min) of solution A (0.1% TFA/water) and solution B (80% ACN/0.1% TFA/water) for 60 minutes. Spectrum scanning was repeated three times for each sample of protein gel spots and tissue hydrolysate. Mass spectra of eluted peptide were simultaneously obtained under positive polarity for 425-1325 m/z range both in MS and MS/MS mode, 2.1 kV applied accumulation of 85000 ions for 50 milliseconds, averages on 2 spectra. Mass spectra were processed with Spectrum Mill MS Proteomics workbench software (Agilent). Proteins were identified using SwissProt Human Database in the following parameters: score ? 7 for peptide and ? 20 for protein, minimum S/N ratio 20, maximum peptide ion charge +4, precursor mass tolerance ? 2.5 Da, product mass tolerance ? 0.7 Da, Proteins identification was accomplished with detection of minimum 3 peaks of the same peptide ion with maximum of 2 missed cleavages.

Microarray data analysis

We used recently published data set [22] from GEO data base (http://www.ncbi.nlm.nih.gov/geo/; accession number GSE14095). We compared 28 pairs of samples (in each pair there was a sample of lesional skin and a sample of healthy skin from the same patient). Values for each sample were normalized by sample median value in order to unify distributions of expression signals. For assessment of differential expression we used paired Welch t-test with FDR correction [23]. Probe set was considered as differentially expressed if its average fold change exceeded 2.5 and FDR corrected p-value was less than 0.01.

Overconnection analysis

All network-based analyses were conducted with MetaCore software suite http://www.genego.com. This software employs a dense and manually curated database of interactions between biological objects and variety of tools for functional analysis of high-throughput data.

We defined a gene as overconnected with the gene set of interest if the corresponding node had more direct interactions with the nodes of interest than it would be expected by chance. Significance of overconnection was estimated using hypergeometric distribution with parameters r - number of interactions between examined node and the list of interest; R - degree of examined node, n -sum of interactions involving genes of interest and N - total number of interactions in the database:


Hidden nodes analysis

In addition to direct interacting objects, we also used objects that may not interact directly with objects of interest but are important upstream regulators of those[24]. The approach is generally the same as described above, but the shortest paths instead of direct links are taken into account. As we were interested in transcriptional regulation, we defined a transcriptional activation shortest path as the preferred shortest path from any object in the MetaCore database to the transcription factor target object from the data set. We added an additional condition to include the uneven number of inhibiting interactions in the path (that's required for the path to have activating effect). If the number of such paths containing examined gene and leading to one of objects of interest were higher than expected by chance, this gene was considered as significant hidden regulator. The significance of a node's importance was estimated using hypergeometric distribution with parameters r - number of shortest paths between containing currently examined gene; R - total number of shortest paths leading to a gene of interest through transcriptional factor, n -total number of transcription activation shortest paths containing examined gene and N - total number of transcription activation shortest paths in the database.

Rank aggregation

Both topology significance approaches produced lists of genes significantly linked to a gene or protein set of interest, ranked by corresponding p-values. To combine results of these two approaches, we used a weighted rank aggregation method described in [25]. Weighted Spearman distance was used as distance measure and the genetic algorithm was employed to select the optimal aggregated list of size 20. This part of work was accomplished in R 2.8.1 http://www.r-project.org.

Network analysis

In addition to topology analysis, we examined overexpressed genes and proteins using various algorithms for selecting connected biologically meaningful subnetworks enriched with objects of interest. Significance of enrichment is estimated using hypergeometric distribution.

We first used an algorithm intended to find regulatory pathways that are presumably activated under pathological conditions. It defines a set of transcription factors that are directly regulating genes of interest and a set of receptors whose ligands are in the list of interest and then constructs series of networks; one for each receptor. Each network contains all shortest paths from a receptor to the selected transcriptional factors and their targets. This approach allows us to reveal the most important areas of regulatory machinery affected under the investigated pathological condition. Networks are sorted by enrichment p-value.

The second applied algorithm used was aimed to define the most influential transcription factors. It considers a transcriptional factor from the data base and gradually expands the subnetwork around it until it reaches a predefined threshold size (we used networks of 50 nodes). Networks are sorted by enrichment p-value.


Results
Differentially abundant proteins

Protein abundance was determined by densitometric quantification of the protein spots on 2D-electophoresis gel (Figure 1; see also Additional file 4) followed by MALDI-TOF mass spectrometry. Total of 10 proteins were over-abundant at least 2-fold in lesional skin compared with uninvolved skin: Keratin 14, Keratin 16, Keratin 17, Squamous cell carcinoma antigen, Squamous cell carcinoma antigen-2, Enolase 1, Superoxide dismutase [Mn], Galectin-7, S100 calcium-binding protein A9 and S100 calcium-binding protein A7 (Table 1). Several of these proteins were previously reported to be over-abundant in psoriatic plaques [26-29].

The proteins belonged to a diverse set of pathways and processes. Thus, keratin 17, keratin 14, and keratin 16 are a member of the keratin gene family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells. SERPINB4 and SERPINB3 are serine protease inhibitor to modulate the host immune response against tumor cells. Enolase 1, more commonly known as alpha-enolase, is a glycolytic enzyme expressed in most tissues, one of the isozymes of enolase. Superoxide dismutase 2 protein (SOD2) transforms toxic superoxide, a byproduct of the mitochondrial electron transport chain, into hydrogen peroxide and diatomic oxygen. Galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Differential and in situ hybridizations indicate that this lectin is specifically expressed in keratinocytes. The cellular localization and its striking down-regulation in cultured keratinocytes imply a role in cell-cell and/or cell-matrix interactions necessary for normal growth control. S100A9 and S100A7 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100A7 is markedly over-expressed in the skin lesions of psoriatic patients.

We attempted to connect the proteins into a network using a collection of over 300,000 manually curated protein interactions and several variants of "shortest path" algorithms applied in MetaCore suite [30] (Figure 2, see Methods for details). The genes encoding overabundant proteins were found to be regulated by several common transcription factors (TFs) including members of the NF-kB and AP-1 complexes, STAT1, STAT3, c-Myc and SP1. Moreover, the upstream pathways activating these TFs were initiated by the overabundant S100A9 through its receptor RAGE [31] and signal transduction kinases (JAK2, ERK, p38 MAPK). This network also included a positive feedback loop as S100A9 expression was determined to be controlled by NF-kB[32]. The topology of this proteomics-derived network was confirmed by several transcriptomics studies [33-38] which showed overexpression of these TFs in psoriasis lesions. Transiently expressed TFs normally have low protein level and, therefore, usually fail to be detected by proteomics methods.

RAGE receptor is clearly the key regulator on this network and plays the major role in orchestrating observed changes of protein abundance. This protein is abundant in both keratinocytes and leukocytes, though normally its expression is low [39]. RAGE participates in a range of processes in these cell types, including inflammation. It is being investigated as a drug target for treatment of various inflammatory disorders [40]. Thus, we may propose that RAGE can also play significant role in psoriasis.

Differentially expressed genes

We used Affymetrix gene expression data set from the recent study [22] involving 33 psoriasis patients. Originally, more than 1300 probe sets were found to be upregulated in lesions as compared with unlesional skin of the same people. We identified 451 genes overexpressed in lesional skin under more stringent statistical criteria (28 samples of lesional skin were matched with their non-lesional counterparts from the same patients in order to exclude individual expression variations, genes with fold change >2.5 and FDR-adjusted p-value < 0.01 were considered as upregulated). The list of overexpressed genes can be found in Additional file 2. The genes encoding 7 out of 10 proteomic markers were overexpressed, well consistent with proteomics data. Expression of Enolase 1, Keratin 14 and Galectin 7 was not altered.

Common transcription regulation for overexpressed genes and differentially abundant proteins

Despite good consistency between the proteomics and expression datasets, the two orders of magnitude difference in list size make direct correlation analysis difficult. Therefore, we applied interactome methods for the analysis of common upstream regulation of the two datasets at the level of transcription factors. First, we defined the sets of the most influential transcription factors using two recently developed methods of interactome analysis [41] and the "hidden nodes" algorithm [42]. The former method ranks TFs based on their one-step overconnectivity with the dataset of interest compared to randomly expected number of interactions. The latter approach takes into account direct and more distant regulation, calculating the p-values for local subnetworks by an aggregation algorithm [42]. We calculated and ranked the top 20 TFs for each data type and added several TFs identified by network analysis approaches (Table 2). The TFs common for both data types were taken as set of 'important pathological signal transducers' (Figure 3). Noticeably, they closely resemble the set of TFs regulating the protein network on Figure 2.

Identification of influential receptors

In the next step, we applied "hidden nodes" algorithm to identify the most influential receptors that could trigger maximal possible transcriptional response. In total, we found 226 membrane receptors significantly involved into regulation of 462 differentially expressed genes ('hidden nodes' p-value < 0.05). The complete list of receptors can be found in Additional file 3. Assuming that topological significance alone does not necessarily prove that all receptors are involved in real signaling or are even expressed in the sample; we filtered this list by expression performance. The receptors used were those whose encoding genes or corresponding ligands were overexpressed greater than 2.5 fold. We assumed that the pathways initiated by over-expressed receptors and ligands are more likely to be activated in psoriasis. Here we assumed that expression alterations and protein abundance are at least collinear. An additional criterion was that the candidate receptors had to participate in the same signaling pathways with at least one of the common TFs. No receptor was rejected based on this criterion.

In total, 44 receptors passed the transcription cut-off. Of these 24 receptor genes were overexpressed; 23 had overexpressed ligands and 3 cases had overexpression of both ligands and receptors (IL2RB, IL8RA and CCR5; see Figures 4 and 5 and Additional file 4). Interestingly, for several receptors, more than one ligand was over-expressed (Figure 4). Several receptors are composed of several subunits, only one of which was upregulated (for example, IL-2 receptor has only gamma subunit gene significantly upregulated).

Out of 44 receptors we identified by topology analysis, 21 were previously reported as psoriasis markers (they are listed in Table 3 with corresponding references). The other 23 receptors were not reported to be linked to psoriasis or known to be implicated in other inflammatory diseases. These receptors belong to different cellular processes (development, cell adhesion, chemotaxis, apoptosis and immune response) (Table 3).


Discussion

Meta-analysis of multiple OMICs data types and studies is becoming an important research tool in understanding complex diseases. Several methods were developed for correlation analysis between the datasets of different type, such as mRNA and proteomics [18,43-46]. However, there are many technological challenges to resolve, including mismatching protein IDs and mRNA probes, fundamental differences in OMICs technologies, differences in experimental set-ups in studies done by different groups etc [47]. Moreover, biological reasons such as differences in RNA and protein degradation processes also contribute to variability of different data types. As a result, transcriptome and proteome datasets usually show only weak positive correlation although were considered as complimentary. More recent studies focused on functional similarities and differences observed for different levels of cellular organization and reflected in different types of OMICs data [48-51]. For example, common interacting objects were found for distinct altered transcripts and proteins in type 2 diabetes [52]. In one leukemia study [53] authors found that distinct alterations at transcriptomics and proteomic levels reflect different sides of the same deregulated cellular processes.

The overall concordance between mRNA and protein expression landscapes was addressed in earlier studies, although the data types were compared mostly at the gene/protein level with limited functional analysis [14,47]. Later, ontology enrichment co-examination of transcriptomics and proteomic data has shown that the two data types affect similar biological processes and are complimentary [49,53,54]. However, the key issue of biological causality and functional consequences of distinct regulation events at both mRNA and protein levels of cellular organization were not yet specifically addressed. These issues cannot be resolved by low resolution functional methods like enrichment analysis. Instead, one has to apply more precise computational methods such as topology and biological networks, which take into consideration directed binary interactions and multi-step pathways connecting objects between the datasets of different types regardless of their direct overlap at gene/protein level [12,13]. For example, topology methods such as "hidden nodes" [24,41] can identify and rank the upstream regulatory genes responsible for expression and protein level alterations while network tools help to uncover functional modules most affected in the datasets, identify the most influential genes/proteins within the modules and suggest how specific modules contribution to clinical phenotype [10,52].

In this study, we observed substantial direct overlap between transcriptomics and proteomics data, as 7 out of 10 over-abundant proteins in psoriasis lesions were encoded by differentially over-expressed genes. However, the two orders of magnitude difference in dataset size (462 genes versus 10 proteins) made the standard correlation methods inapplicable. Besides, proteomics datasets display a systematic bias in function of abundant proteins, favoring "effector" proteins such as structural, inflammatory, core metabolism proteins but not the transiently expressed and fast degradable signaling proteins. Therefore, we applied topological network methods to identify common regulators for two datasets such as the most influential transcription factors and receptors. We have identified some key regulators of the "proteomics" set among differentially expressed genes, including transcription factors, membrane receptors and extracellular ligands, thus reconstructing upstream signaling pathways in psoriasis. In particular, we identified 24 receptors previously not linked to psoriasis.

Importantly, many ligands and receptors defined as putative starts of signaling pathways were activated by transcription factors at the same pathways, clearly indicating on positive regulatory loops activated in psoriasis. The versatility and the variety of signaling pathways activated in psoriasis is also impressive, which is evident from differentially overexpression of 44 membrane receptors and ligands in skin lesions. This complexity and redundancy of psoriasis signaling likely contributes to the inefficiency of current treatments, even novel therapies such as monoclonal antibodies against TNF-? and IL-23. Thus, the key regulator, RAGE receptor, triggers multiple signaling pathways which stay activated even when certain immunological pathways are blocked. Our study suggests that combination therapy targeting multiple pathways may be more efficient for psoriasis (particularly considering feasibility for topical formulations). In addition, the 24 receptors we identified by topology analysis and previously not linked with psoriasis can be tested as potential novel targets for disease therapy.

The functional machinery of psoriasis is still not complete and additional studies can be helpful in "filling the gaps" of our understanding of its molecular mechanisms. For instance, kinase activity is still unaccounted for, as signaling kinases are activated only transiently and are often missed in gene expression studies. Topological analysis methods such as "hidden nodes" [24] may help to reconstruct regulatory events missing in the data. Also, the emerging phosphoproteomics methodology may prove to become a helpful and complimentary OMICs technology. The network analysis methodology is not dependent on the type of data analyzed and or any gene/protein content overlap between the studies and is well applicable for functional integration of multiple data types.


Conclusion

We have successfully applied network-based methods to integrate and explore two distinct high-throughput disease data sets of different origin and size. Through identification of common regulatory machinery that is likely to cause overexpression of genes and proteins, we came to the signaling pathways that might contribute to the altered state of regulatory network in psoriatic lesion. Our approach allows easy integrative investigation of different data types and produces biologically meaningful results, leading to new potential therapy targets. We have demonstrated that pathology can be caused and maintained by a great amount of various cascades, many previously not described as implicated in psoriasis; therefore, combined therapies targeting multiple pathways might be effective in treatment.


Authors' contributions

EP and TN conceived the study and participated in its design and coordination; SB, SM and StM performed the proteomics analysis of psoriatic tissues, AI performed statistical and network-based analyses and wrote the manuscript, RA helped with bioinformatical analysis of the data, YN edited the manuscript. All authors have read and approved the manuscript.


Supplementary Material Additional file 1

Table S1. Patient description


Click here for additional data file (1752-0509-4-41-S1.DOCX)

Additional file 2

Table S2. List of genes significantly upregulated in lesions at the mRNA level


Click here for additional data file (1752-0509-4-41-S2.XLSX)

Additional file 3

Table S3. List of receptors significantly involved in regulation of genes overexpressed in psoriatic plaque ('hidden nodes' algorithm result)


Additional file 4

Legend. Network layout legend explaining meaning of object icons and interaction types


Click here for additional data file (1752-0509-4-41-S4.PDF)


Acknowledgements

This work was supported by grant 02.512.11.2042 from Ministry of Science and Technologies of Russian Federation, and grant from Russian Academy of Sciences ("Fundamental Sciences to Medicine" program)


References
Boehncke WH,Pulling the trigger on psoriasisNatureYear: 1996379656877710.1038/379777a08587600
Ortonne JP,Aetiology and pathogenesis of psoriasisBr J DermatolYear: 1996135Suppl 491510.1111/j.1365-2133.1996.tb15660.x9035700
Pastore S,Biological drugs targeting the immune response in the therapy of psoriasisBiologicsYear: 2008246879719707449
Gisondi P,Girolomoni G,Biologic therapies in psoriasis: a new therapeutic approachAutoimmun RevYear: 200768515910.1016/j.autrev.2006.12.00217854741
Oestreicher JL,Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profilingPharmacogenomics JYear: 2001142728711911124
Bowcock AM,Insights into psoriasis and other inflammatory diseases from large-scale gene expression studiesHum Mol GenetYear: 20011017179380510.1093/hmg/10.17.179311532989
Zhou X,Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide arrayPhysiol GenomicsYear: 2003131697812644634
Quekenborn-Trinquet V,Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severityBr J DermatolYear: 2005152348950410.1111/j.1365-2133.2005.06384.x15787818
Nikolskaya T,Network analysis of human glaucomatous optic nerve head astrocytesBMC Med GenomicsYear: 200922410.1186/1755-8794-2-2419426536
Nikolsky Y,Nikolskaya T,Bugrim A,Biological networks and analysis of experimental data in drug discoveryDrugDiscov TodayYear: 20051096536210.1016/S1359-6446(05)03420-3
Bhavnani SK,Network analysis of genes regulated in renal diseases: implications for a molecular-based classificationBMC BioinformaticsYear: 200910Suppl 9S310.1186/1471-2105-10-S9-S319761573
Ideker T,Sharan R,Protein networks in diseaseGenome ResYear: 20081846445210.1101/gr.071852.10718381899
Chuang HY,Network-based classification of breast cancer metastasisMol Syst BiolYear: 2007314010.1038/msb410018017940530
Cox B,Kislinger T,Emili A,Integrating gene and protein expression data: pattern analysis and profile miningMethodsYear: 20053533031410.1016/j.ymeth.2004.08.02115722226
Wise LH,Lanchbury JS,Lewis CM,Meta-analysis of genome searchesAnn Hum GenetYear: 199963Pt 32637210.1046/j.1469-1809.1999.6330263.x10738538
Ghosh D,Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancerFunct Integr GenomicsYear: 200334180810.1007/s10142-003-0087-512884057
Warnat P,Eils R,Brors B,Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypesBMC BioinformaticsYear: 2005626510.1186/1471-2105-6-26516271137
Hack CJ,Integrated transcriptome and proteome data: the challenges aheadBrief Funct Genomic ProteomicYear: 200433212910.1093/bfgp/3.3.21215642185
Menezes R,Integrated analysis of DNA copy number and gene expression microarray data using gene setsBMC BioinformaticsYear: 200910120310.1186/1471-2105-10-20319563656
Gravel P,Golaz O,Two-Dimensional PAGE Using Carrier Ampholyte pH Gradients in the First DimensionThe Protein Protocols HandbookYear: 1996127132 full_text.
Mortz E,Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysisProteomicsYear: 200111113596310.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q11922595
Yao Y,Type I interferon: potential therapeutic target for psoriasis?PLoS OneYear: 200837e273710.1371/journal.pone.000273718648529
Benjamini Y,Hochberg Y,Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society. Series B, MethodologicalYear: 1995571289300
Dezso Z,Identifying disease-specific genes based on their topological significance in protein networksBMC Syst BiolYear: 200933610.1186/1752-0509-3-3619309513
Pihur V,Datta S,RankAggreg, an R package for weighted rank aggregationBMC BioinformaticsYear: 2009106210.1186/1471-2105-10-6219228411
Leigh IM,Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitroThe British journal of dermatologyYear: 1995133450151110.1111/j.1365-2133.1995.tb02696.x7577575
Madsen P,Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skinThe Journal of investigative dermatologyYear: 199197470171210.1111/1523-1747.ep124840411940442
Vorum H,Expression and divalent cation binding properties of the novel chemotactic inflammatory protein psoriasinElectrophoresisYear: 1996171117879610.1002/elps.11501711188982613
Takeda A,Overexpression of serpin squamous cell carcinoma antigens in psoriatic skinJ Invest DermatolYear: 200211811475410.1046/j.0022-202x.2001.01610.x11851888
Nikolsky Y,Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platformMethods in molecular biology (Clifton, N.J.)Year: 2009563177196 full_text. 19597786
Ghavami S,S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathwayJournal of leukocyte biologyYear: 20088361484149210.1189/jlb.060739718339893
Schreiber J,Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharideProc Natl Acad Sci USAYear: 200610315589990410.1073/pnas.051099610316595631
Tsuruta D,NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasisRecent Pat Inflamm Allergy Drug DiscovYear: 20093140810.2174/18722130978715839919149745
Sano S,Chan KS,DiGiovanni J,Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseasesJ Dermatol SciYear: 200850111410.1016/j.jdermsci.2007.05.01617601706
Ghoreschi K,Mrowietz U,Rocken M,A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responsesJ Mol MedYear: 20038184718010.1007/s00109-003-0460-912879154
Piruzian ES,[The comparative analysis of psoriasis and Crohn disease molecular-genetical processes under pathological conditions]Mol Biol (Mosk)Year: 2009431175919334540
Gandarillas A,Watt FM,c-Myc promotes differentiation of human epidermal stem cellsGenes DevYear: 1997112128698210.1101/gad.11.21.28699353256
Arnold I,Watt FM,c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progenyCurr BiolYear: 20011185586810.1016/S0960-9822(01)00154-311369200
Lohwasser C,The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alphaJ Invest DermatolYear: 20061262291910.1038/sj.jid.570007016374460
Santilli F,Soluble forms of RAGE in human diseases: clinical and therapeutical implicationsCurr Med ChemYear: 20091689405210.2174/09298670978758188819275604
Nikolsky Y,Genome-wide functional synergy between amplified and mutated genes in human breast cancerCancer researchYear: 200868229532954010.1158/0008-5472.CAN-08-308219010930
Nikolskaya T,Network analysis of human glaucomatous optic nerve head astrocytesBMC medical genomicsYear: 2009212410.1186/1755-8794-2-2419426536
Le Naour F,Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomicsJ Biol ChemYear: 200127621179203110.1074/jbc.M10015620011279020
Steiling K,Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokersPLoS OneYear: 200944e504310.1371/journal.pone.000504319357784
Conway JP,Kinter M,Proteomic and transcriptomic analyses of macrophages with an increased resistance to oxidized low density lipoprotein (oxLDL)-induced cytotoxicity generated by chronic exposure to oxLDLMol Cell ProteomicsYear: 200541015224010.1074/mcp.M500111-MCP20016006650
Di Pietro C,The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastomaBMC Med GenomicsYear: 2009212010.1186/1755-8794-2-2019402918
Mijalski T,Identification of coexpressed gene clusters in a comparative analysis of transcriptome and proteome in mouse tissuesProceedings of the National Academy of Sciences of the United States of AmericaYear: 2005102248621862610.1073/pnas.040767210215939889
Habermann JK,Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesisGenes Chromosomes CancerYear: 2007461102610.1002/gcc.2038217044061
Chen YR,Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cellsJ Proteome ResYear: 200651027274210.1021/pr060212g17022644
Shachaf CM,Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenanceCancer ResYear: 2008681351324210.1158/0008-5472.CAN-07-619218593912
Zhao C,Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methodsJournal of Proteome ResearchYear: 2009884028403810.1021/pr900364p19514703
Gerling IC,New data analysis and mining approaches identify unique proteome and transcriptome markers of susceptibility to autoimmune diabetesMol Cell ProteomicsYear: 20065229330516227630
Zheng PZ,Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemiaProc Natl Acad Sci USAYear: 2005102217653810.1073/pnas.050282510215894607
Zhao C,Identification of Novel Functional Differences in Monocyte Subsets Using Proteomic and Transcriptomic MethodsJ Proteome ResYear: 200919514703
Reichrath J,Expression of integrin subunits and CD44 isoforms in psoriatic skin and effects of topical calcitriol applicationJ Cutan PatholYear: 199724849950610.1111/j.1600-0560.1997.tb01324.x9331896
Kelly R,Marsden RA,Bevan D,Exacerbation of psoriasis with GM-CSF therapyBr J DermatolYear: 19931284468910.1111/j.1365-2133.1993.tb00218.x8494766
Gu J,A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patientsRheumatology (Oxford)Year: 20024177596610.1093/rheumatology/41.7.75912096225
Reischl J,Increased expression of Wnt5a in psoriatic plaquesJ Invest DermatolYear: 20071271163910.1038/sj.jid.570048816858420
Shiina T,The HLA genomic loci map: expression, interaction, diversity and diseaseJ Hum GenetYear: 2009541153910.1038/jhg.2008.519158813
Asadullah K,IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approachJ Clin InvestYear: 199810147839410.1172/JCI14769466973
Cancino-Diaz JC,Interleukin-13 receptor in psoriatic keratinocytes: overexpression of the mRNA and underexpression of the proteinJ Invest DermatolYear: 2002119511142010.1046/j.1523-1747.2002.19509.x12445201
Pietrzak A,Genes and structure of selected cytokines involved in pathogenesis of psoriasisFolia Histochem CytobiolYear: 2008461112110.2478/v10042-008-0002-y18296259
Martin R,Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?Trends Pharmacol SciYear: 20032412613610.1016/j.tips.2003.10.00614654299
Penna G,Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3BloodYear: 2005106103490710.1182/blood-2005-05-204416030186
Fu X,Estimating accuracy of RNA-Seq and microarrays with proteomicsBMC GenomicsYear: 200910116110.1186/1471-2164-10-16119371429
Foell D,Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritisRheumatology (Oxford)Year: 200342111383910.1093/rheumatology/keg38512832707
Horuk R,BX471: a CCR1 antagonist with anti-inflammatory activity in manMini Rev Med ChemYear: 20055979180410.2174/138955705486705716178722
Vestergaard C,Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasisActa Derm VenereolYear: 2004845353810.1080/0001555041003444415370700
Rottman JB,Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgarisLab InvestYear: 20018133354711310827
de Groot M,Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitorArch Dermatol ResYear: 200729973051310.1007/s00403-007-0764-717647003
Ellis CN,Krueger GG,Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytesN Engl J MedYear: 200134542485510.1056/NEJM20010726345040311474662
De Rie MA,Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skinClin Exp DermatolYear: 19962121041110.1111/j.1365-2230.1996.tb00030.x8759195
Prens E,Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous MECLR in psoriasisArch Dermatol ResYear: 19962882687310.1007/BF025050468932583
Haider AS,Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patientsJ ImmunolYear: 2007178117442917513795
Castelijns FA,The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasisJ Am Acad DermatolYear: 1999406 Pt 1901910.1016/S0190-9622(99)70077-010365920
Johansen C,Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinBr J DermatolYear: 200916023192410.1111/j.1365-2133.2008.08902.x19016708
Debets R,The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermisJ ImmunolYear: 199715862955639058835
Schulz BS,Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitroJ ImmunolYear: 1993151843994067691948
Guttman-Yassky E,Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsivenessJ Invest DermatolYear: 2008128511829110.1038/jid.2008.418239614
Sjogren F,Expression and function of beta 2 integrin CD11B/CD18 on leukocytes from patients with psoriasisActa Derm VenereolYear: 19997921051010.1080/00015559975001129110228626
Curry JL,Innate immune-related receptors in normal and psoriatic skinArch Pathol Lab MedYear: 200312721788612562231
Vissers WH,Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear lateBr J DermatolYear: 20041505852910.1111/j.1365-2133.2004.05863.x15149496
Patterson AM,Differential expression of syndecans and glypicans in chronically inflamed synoviumAnn Rheum DisYear: 200867559260110.1136/ard.2006.06387517545191
Wakita H,Takigawa M,E-selectin and vascular cell adhesion molecule-1 are critical for initial trafficking of helper-inducer/memory T cells in psoriatic plaquesArch DermatolYear: 199413044576310.1001/archderm.130.4.4577513146
Chu A,Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammationJ ImmunolYear: 1999163950869310528215
Seung NR,Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasisJ Cutan PatholYear: 200734129031110.1111/j.1600-0560.2007.00756.x18001412

Figures

[Figure ID: F1]
Figure 1 

Representative silver-stained 2DE gel images of lesional and uninvolved skin biopsy lysates. a) - gel image of lesional skin biopsy lysate; b) - gel image of uninvolved skin biopsy lysate. Spots corresponding to proteins overexpressed in lesions are marked with red rectangles and numbered. Spot 1 correspond to 3 proteins of keratin family, spot 2 - SCCA2, spot 3 - SCCA1, spot 4 - enolase 1, spot 5 - SOD2, spot 6 - galectin-7. S100A7 is found in spots 7 and 8 and S100A9 corresponds to 9th and 10th spots.



[Figure ID: F2]
Figure 2 

Network illustrating regulatory pathways leading to transcription activation of proteomics markers. Red circles denote upregulated proteins. Designations of network objects and interaction types can be found in Additional file 4.



[Figure ID: F3]
Figure 3 

Common transcriptional factors important for regulation of objects at both transcriptomics and proteomic levels. Objects in MetaCore database representing transcriptional factors found to be important regulators of pathology-related genes. Red circles denote that corresponding gene is upregulated in psoriatic lesion. Designations of network objects and interaction types can be found in Additional file 4.



[Figure ID: F4]
Figure 4 

Candidate receptors with their respective upregulated ligands. Initial steps of pathways presumably activated in lesions (ligands, overexpressed at transcriptional level and their corresponding receptors) Red circles denote that corresponding gene is upregulated in psoriatic lesion. Designations of network objects and interaction types can be found in Additional file 4.



[Figure ID: F5]
Figure 5 

Upregulated candidate receptors with their respective ligands. Initial steps of pathways presumably activated in lesions (receptors, overexpressed at transcriptional level and their corresponding ligands) Red circles denote that corresponding gene is upregulated in psoriatic lesion. Designations of network objects and interaction types can be found in Additional file 4.



Tables
[TableWrap ID: T1] Table 1 

Proteins with elevated expression in lesions


Protein name Gene Fold change
Keratin 17 KRT17 10.94444444
Keratin 14 KRT14 10.94444444
Keratin 16 KRT16 10.94444444
SCCA2/SCCA1 fusion protein isoform 2 SERPINB4 4.242424242
squamous cell carcinoma antigen; SCC antigen SERPINB3 11.66666667
Enolase 1 ENO1 2.175
Superoxide dismutase [Mn] SOD2 2
Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1) LGALS7B 6
Protein S100-A9 (S100 calcium-binding protein A9) S100A9 Lesion only
Protein S100-A7 (S100 calcium-binding protein A7) (Psoriasin) S100A7 Lesion only

[TableWrap ID: T2] Table 2 

Common transcriptional factors for proteomics and expression datasets


Transcriptomics Proteomics
Entrez ID Gene Over-connection P-Value Hidden nodes P-Value Entrez ID Gene Over-connection P-Value Hidden nodes P-Value
6772 STAT1 4.081E-28 1.027E-22 2736 GLI2 4.318E-03 2.080E-04
3659 IRF1 1.344E-22 3.203E-19 6772 STAT1 2.234E-04 1.293E-04
4790 NFKB1 3.677E-13 2.523E-25 3091 HIF1A 2.345E-03 2.402E-04
5970 RELA 3.726E-14 4.120E-24 6778 STAT6 9.420E-04 2.080E-04
5966 REL 4.844E-17 3.580E-16 7392 USF2 1.507E-04 -
6688 SPI1 7.019E-13 1.245E-16 6774 STAT3 2.542E-05 -
3394 IRF8 7.594E-12 1.903E-16 6776 STAT5A - 2.820E-05
1051 CEBPB 1.590E-12 1.271E-15 668 FOXL2 1.100E-02 1.388E-03
2908 NR3C1 2.307E-05 1.504E-17 2078 ERG 2.386E-04 1.388E-03
10379 IRF9 8.193E-05 4.037E-17 6777 STAT5B - 2.820E-05
3660 IRF2 3.794E-12 3.914E-09 7020 TFAP2A 4.806E-04 -
6434 SFRS10 - 4.420E-17 5371 PML 1.177E-03 -
6775 STAT4 1.637E-03 5.842E-16 2735 GLI1 1.053E-02 -
6667 SP1 5.508E-12 2.013E-07 6667 SP1 3.269E-05 -
6777 STAT5B 2.725E-04 2.063E-15 3725 JUN 1.198E-03 -
3725 JUN 2.182E-11 7.521E-11 8462 KLF11 6.710E-03 2.775E-03
6774 STAT3 9.643E-10 2.114E-11 2099 ESR1 1.650E-02 -
7157 TP53 9.352E-10 7.171E-08 10538 BATF 1.765E-02 -
30009 TBX21 5.119E-03 1.594E-14 30009 TBX21 - 1.911E-04
1874 E2F4 1.537E-09 8.737E-07 7421 VDR - 1.693E-04
Additional TFs identified by subnetwork-based analysis
4609 MYC 2.680E-69 - 4609 MYC 1.120E-07 -
5966 REL 1.120E-07 -
5970 RELA 1.120E-07 -
4790 NFKB1 1.120E-07 -

Some genes were considered significant only by one of two topological approaches (this is evident for proteomics data, where low number of proteins limits capabilities of topological analysis). Missing p-value means that correspondent gene has not passed 0.05 significance threshold and has been listed among top factors only due to low p-value for other topological approach. Only one p-value was determined in the case of network analysis (enrichment p-value for the network built around seed transcription factor). Transcriptional factors common for proteomics and transcriptomics level are in bold text.


[TableWrap ID: T3] Table 3 

Receptors identified in our study and not yet studied in connection to psoriasis


Gene Protein Entrez Gene ID Connection to psoriasis
EPHA2 Ephrin-A receptor 2 1969 No
EPHB2 Ephrin-B receptor 2 2048 No
FCER1G Fc epsilon RI gamma 2207 No
INSR Insulin receptor 3643 No
LTBR LTBR(TNFRSF3) 4055 No
PLAUR PLAUR (uPAR) 5329 No
TNFRSF10A DR4(TNFRSF10A) 8797 No
TNFRSF10B DR4(TNFRSF10A) 8795 No
CD44 CD44 960 Possible[55]
CSF2RB CSF2RB 1439 Possible[56]
CXCR4 CXCR4 7852 Possible[57]
FZD4 FZD4 8322 Possible[58]
GABBR1 GBR1 2550 Possible[59]
IL10RA IL10RA 3587 Possible[60]
IL13RA1 IL13RA1 3597 Possible[61]
IL2RB IL-2R beta chain 3560 Possible[62]
IL2RG IL-2R gamma chain 3561 Possible[62]
IL4R IL4RA 3566 Possible[63]
LILRB2 ILT4 10288 Possible[64]
LRP2 LRP2 (Megalin) 4036 Possible[65]
LRP8 APOER2 7804 Possible[65]
ROR2 ROR2 4920 Possible[58]
AGER RAGE 177 Yes[66]
CCR1 CCR1 1230 Yes[67]
CCR2 CCR2 1231 Yes[68]
CCR3 CCR3 1232 Yes[69]
CCR5 CCR5 1234 Yes[70]
CD2 CD2 914 Yes[71]
CD27 CD27(TNFRSF7) 939 Yes[72]
CD36 CD36 948 Yes[73]
CD3D CD3 delta 915 Yes[74]
EGFR EGFR 1956 Yes[75]
IL17RA IL-17 receptor 23765 Yes[76]
IL1R1 IL-1RI 3554 Yes[77]
IL8RA IL8RA 3577 Yes[78]
IL8RB IL8RB 3579 Yes[78]
ITGAL ITGAL 3683 Yes[79]
ITGB2 ITGB2 3689 Yes[80]
LRP1 A2 M receptor 4035 Yes[81]
PTPRC CD45 5788 Yes[82]
SDC3 Syndecan-3 9672 Yes[83]
SELE E-selectin 6401 Yes[84]
SELPLG PSGL-1 6404 Yes[85]
TLR4 TLR4 7099 Yes[86]

'Possible' term was used if protein name co-occurred with psoriasis in articles, but no clear evidence of its implication was shown. In some cases, ligands are associated with psoriasis (i.e, IL-10).



Article Categories:
  • Research article


Previous Document:  Exocrine-to-endocrine differentiation is detectable only prior to birth in the uninjured mouse pancr...
Next Document:  Distinct evolutionary histories of the DNA-A and DNA-B components of bipartite begomoviruses.